Legend Biotech Corp.

Johnson & Johnson has sought to carve out a leading position in the treatment of multiple myeloma, and presentations at the American Society of Clinical Oncology and European Hematology Associatio

Bristol Myers Squibb’s CAR-T cell therapy Breyanzi (lisocabtagene maraleucel) may see an expansion in its addressable population with positive Phase II data in marginal zone lymphoma (MZL). The drugma

With new long-term survival data at the recently concluded American Society of Clinical Oncology meeting, Johnson & Johnson and Legend Biotech are less and less shy about using the word “cure” in

The 2025 American Society of Clinical Oncology conference will take place in Chicago from 30 May-3 June, and while it typically leans toward solid tumors, it also often features a number of important